The acute lymphocytic leukemia (ALL) cell therapy market size was valued at $2.3 billion in 2021. Acute lymphocytic (or lymphoid or lymphoblastic) leukemia (ALL) is a malignancy of the hematopoietic system caused by the abnormal proliferation or differentiation of lymphoid progenitors in the bone marrow. ALL is classified into two main subtypes: T-ALL, which accounts for approximately 20% of total cases, and B-cell ALL (B-ALL). Diagnosis of ALL is dependent on cytogenetics, cell morphology, and immunotyping.
For more insights on the acute lymphocytic leukemia (ALL) cell therapy market forecasts, read our free sample report
Acute Lymphocytic Leukemia (ALL) Cell Therapy Market FAQs
- What was the acute lymphocytic leukemia (ALL) cell therapy market size in 2021?
The acute lymphocytic leukemia (ALL) cell therapy market size valued at $2.3 billion in 2021. - Which are the key regions in the acute lymphocytic leukemia (ALL) cell therapy market?
The key regions in the acute lymphocytic leukemia (ALL) cell therapy market are APAC, Europe, the Middle East, and North America. - Which region dominated the acute lymphocytic leukemia (ALL) cell therapy market?
North America dominated the acute lymphocytic leukemia (ALL) cell therapy market. - Who are the leading players in the acute lymphocytic leukemia (ALL) cell therapy market?
Some of the leading players in the acute lymphocytic leukemia (ALL) cell therapy market are Hebei Senlang Biotechnology, Chongqing Precision Biotech, Sian Wuhan Medical Technology Co Ltd, Novartis AG, iCell Gene Therapeutics LLC, and Wugen Inc
For more queries on the acute lymphocytic leukemia (ALL) cell therapy market, view the report sample
Acute Lymphocytic Leukemia (ALL) Cell Therapy Market Dynamics
Established CAR-T therapies to grow market share via label expansions: Kymriah is expected to move into 1L, and Tecartus is expected to achieve a label for the pediatric patient population. The inability to find a donor for stem cell transplants drives the need for stem cell replacement products such as NiCord and TRGFT-201. The need for “off-the-shelf” products with lower costs and reduced infrastructure requirements drives the development of allogeneic agents.
Pipeline cell therapies will face significant competition from marketed CAR-Ts, which have become established in the ALL setting. The first-line setting is well-served by chemotherapy, with high use of stem cell transplants on relapse. This blocks the entry of cell therapies into more lucrative settings. The lack of established target antigens in T-ALL decreases R&D for this patient population.
For additional insights on acute lymphocytic leukemia (ALL) cell therapy market dynamics, download a free sample report
Acute Lymphocytic Leukemia (ALL) Cell Therapy Market Regional Insights
The key regions in the acute lymphocytic leukemia (ALL) cell therapy market are North America, Europe, Middle East, and APAC. North America dominated the market share in 2021. The 15 markets comprise the 8MM and seven countries known to have increased potential for cell therapies given the current drug development landscape including Australia, Belgium, Canada, Denmark, Israel, South Korea, and Switzerland.
For more regional insights on the acute lymphocytic leukemia (ALL) cell therapy market, download report sample
Acute Lymphocytic Leukemia (ALL) Cell Therapy Market – Leading Players
Some of the future players in the acute lymphocytic leukemia cell therapy market are Hebei Senlang Biotechnology, Chongqing Precision Biotech, Sian Wuhan Medical Technology Co Ltd, Novartis AG, iCell Gene Therapeutics LLC, and Wugen Inc among others. Hebei Senlang Biotechnology and Chongqing Precision Biotech are the leading sponsors of cell therapy trials in the ALL market.
Get a free sample for additional insights into the acute lymphocytic leukemia cell therapy market
Related Report
- Preface
1.1. Contents
1.2. Report Scope
- Executive Summary
- Disease Overview
3.1. Etiology & Epidemiology
3.2. ALL Treatment Algorithm
- Pipeline Drugs Overview
4.1. Pipeline Analysis
4.2. Target Analysis and Clinical Benchmarks
- Market Outlook
5.1. 10-Year Market Analysis with Drivers and Barriers
- Unmet Needs
- Likelihood of Approval Analysis and Phase Transition Success Rate Analysis
- Competitive Assessment
8.1. Competitive Analysis by Class of Therapy
- Future Players
9.1. Future Players Based on Pipeline Strength
- Appendix
10.1. Cell Therapies Forecast Methodology Overview
10.2. Pricing of Cell Therapies
10.3. Pipeline Launch Assumptions
10.4. Abbreviations
10.5. Methodology
10.6. About the Authors
- Contact Us
About us
GlobalData is a leading provider of data, analytics, and insights on the world’s largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision-makers to predict and navigate the future. GlobalData’s mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on us for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
+44 (0)207 936 6400
Contact Information:
Media Contacts GlobalData Mark Jephcott Head of PR EMEA [email protected] cc: [email protected] +44 (0)207 936 6400
Tags:
Reportedtimes, PR-Wirein, iCN Internal Distribution, Extended Distribution, Research Newswire, English